These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39127699)

  • 41. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
    Fujio S; Hanaya R
    No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling.
    Hölsken A; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
    Acta Neuropathol; 2010 May; 119(5):631-9. PubMed ID: 20131060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations.
    Fujio S; Juratli TA; Takajo T; Arita K; Nagano Y; Yoshimoto K; Nayyar N; Curry WT; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
    Neurol Med Chir (Tokyo); 2021 Jun; 61(6):385-391. PubMed ID: 33967180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
    Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
    Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.
    Buslei R; Nolde M; Hofmann B; Meissner S; Eyupoglu IY; Siebzehnrübl F; Hahnen E; Kreutzer J; Fahlbusch R
    Acta Neuropathol; 2005 Jun; 109(6):589-97. PubMed ID: 15891929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
    Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
    Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance.
    Wang X; Zhao C; Lin J; Liu H; Zeng Q; Chen H; Wang Y; Xu D; Chen W; Xu M; Zhang E; Lin D; Lin Z
    Chin Med J (Engl); 2024 Apr; 137(7):859-870. PubMed ID: 37565822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas.
    Gomes DC; Jamra SA; Leal LF; Colli LM; Campanini ML; Oliveira RS; Martinelli CE; Elias PC; Moreira AC; Machado HR; Saggioro F; Neder L; Castro M; Antonini SR
    Eur J Endocrinol; 2015 May; 172(5):603-8. PubMed ID: 25693592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma.
    Haston S; Pozzi S; Carreno G; Manshaei S; Panousopoulos L; Gonzalez-Meljem JM; Apps JR; Virasami A; Thavaraj S; Gutteridge A; Forshew T; Marais R; Brandner S; Jacques TS; Andoniadou CL; Martinez-Barbera JP
    Development; 2017 Jun; 144(12):2141-2152. PubMed ID: 28506993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrative analyses identify HIF-1α as a potential protective role with immune cell infiltration in adamantinomatous craniopharyngioma.
    Gao Q; Luo J; Pan J; Zhang L; Song D; Zhang M; Xu D; Guo F
    Front Immunol; 2022; 13():949509. PubMed ID: 36091021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
    Hölsken A; Kreutzer J; Hofmann BM; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
    Brain Pathol; 2009 Jul; 19(3):357-64. PubMed ID: 18540944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of CTNNB1 Mutation Status in Pediatric Cystic Adamantinomatous Craniopharyngioma by Using Preoperative Magnetic Resonance Imaging Manifestation.
    Zhu W; Tang T; Yuan S; Chang B; Li S; Chen M
    Clin Neurol Neurosurg; 2021 Jan; 200():106347. PubMed ID: 33160718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of chromosomal imbalances in adamantinomatous and papillary craniopharyngiomas.
    Rickert CH; Paulus W
    J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):260-1. PubMed ID: 12531965
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models.
    Martinez-Barbera JP; Buslei R
    J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):7-17. PubMed ID: 25503464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy.
    Zuhur SS; Tanik C; Erol RS; Musluman AM; Kabukcuoglu F; Altuntas Y
    Turk Neurosurg; 2013; 23(1):55-60. PubMed ID: 23344868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiomics integration-based immunological characterizations of adamantinomatous craniopharyngioma in relation to keratinization.
    Xu C; Wu J; Ye J; Si Y; Zhang J; Wu B; Pan L; Fu J; Ren Q; Xie S; Tang B; Xiao Y; Hong T
    Cell Death Dis; 2024 Jun; 15(6):439. PubMed ID: 38906852
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In-depth proteomic profiling captures subtype-specific features of craniopharyngiomas.
    Kim JH; Kim H; Dan K; Kim SI; Park SH; Han D; Kim YH
    Sci Rep; 2021 Oct; 11(1):21206. PubMed ID: 34707096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
    Zhou J; Zhang C; Pan J; Chen L; Qi ST
    Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
    Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
    J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics and factors influencing hypothalamic pituitary dysfunction in patients with craniopharyngioma.
    Guo Y; Pei L; Li Y; Li C; Gui S; Ni M; Liu P; Zhang Y; Zhong L
    Front Endocrinol (Lausanne); 2023; 14():1180591. PubMed ID: 37324266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.